BioSpace News Archive

AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease (AD), today announced that it will present data on their lead candidate AD101 at the 15th Clinical Trials on Alzheimer’s Disease Conference (CTAD) on November 29 – December 2 in San Francisco, CA.

Verismo Therapeutics, a clinical-stage CAR-T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, announced its new Research and Development Center located at CIC Philadelphia.

Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg.

Autobahn Therapeutics today announced the initiation of dosing in the company’s Phase 1 clinical trial of ABX-002 in healthy volunteers.

Zymeworks Inc. today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement of zanidatamab, a HER2-targeted bispecific antibody, with Jazz Pharmaceuticals has expired.

Bryn Pharma LLC today announced the appointments of Sandy Loreaux and William D. Humphries to its Board of Directors.

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer.

Longboard Pharmaceuticals, Inc. today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of developmental and epileptic encephalopathies (DEEs), in two poster sessions at the 2022 AES Annual Meeting.

PreciseDx, a leading AI company leveraging the analysis of morphology features from histology slides to provide more precise patient-specific risk information, today announced a collaboration with the Laboratory of Pathology at Dordrecht, Netherlands.